Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

Bank stocks largely boosted the Dow, as investors hope the sector could see weaker regulation in a second Trump ...

U.S. equities continued their post-election rally at midday, fueled by optimism that the new Trump administration will be a ...

I have schizoaffective disorder, bipolar type — a combination of schizophrenia and bipolar disorder — and I agree that this is a monumental development for my community. Historically ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.